SCHEMBL477875

SCHEMBL477875

COC(=O)c1cc(C(F)(F)F)ccc1CO

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CFTR P13569 1/20 0.59
CES2 O00748 2/20 0.47
MRGPRX4 Q96LA9 2/20 0.47
KDM4E B2RXH2 4/20 0.43
RXRA P19793 6/20 0.43
NR1H2 P55055 6/20 0.43
NR1H3 Q13133 4/20 0.43
NOTUM Q6P988 1/20 0.42
ALDH1A1 P00352 2/20 0.41
HPGD P15428 2/20 0.41
MEN1 O00255 1/20 0.41
LMNA P02545 1/20 0.41
MAPT P10636 1/20 0.41
RECQL P46063 1/20 0.41
KMT2A Q03164 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.40
CYP2C19 P33261 2/20 0.40
USP2 O75604 1/20 0.40
HSD17B10 Q99714 1/20 0.40
ESRRA P11474 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13730307 0.89 CFTR (0.60) CFTRCES2MRGPRX4KDM4ERXRA
SCHEMBL1435026 0.86 CFTR (0.57) CFTRCES2MRGPRX4KDM4ERXRA
SCHEMBL4107553 0.84 CFTR (0.55) CFTRCES2MRGPRX4KDM4ERXRA
SCHEMBL12310503 0.83 CFTR (0.45) CFTRMRGPRX4KDM4ERXRANR1H2
SCHEMBL27366276 0.82 CFTR (0.54) CFTRCES2MRGPRX4KDM4ERXRA
SCHEMBL22263091 0.82 CFTR (0.73) CFTRCES2MRGPRX4KDM4ENOTUM
SCHEMBL8477461 0.80 ALDH1A1 (0.54) CES2MRGPRX4KDM4EALDH1A1HPGD
SCHEMBL7565893 0.80 TAS2R14 (0.54) CFTRMRGPRX4KDM4EHPGDLMNA
SCHEMBL8227206 0.80 CYP2C9 (0.55) KDM4EALDH1A1HPGDMEN1LMNA
SCHEMBL25085889 0.79 CFTR (0.65) CFTRCES2MRGPRX4KDM4ENOTUM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2851366-A1 Compounds as cannabinoid receptor ligands Abbvie Inc. (US) 2015-03-25 EP disclosed
US-8492371-B2 Compounds as cannabinoid receptor ligands ABBVIE INC. (US) 2013-07-23 US disclosed
CN-102448957-A Compounds as cannabinoid receptor ligands ABBOTT LAB 2012-05-09 CN disclosed
EP-2411382-A1 COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS Abbott Laboratories (US) 2012-02-01 EP disclosed
US-20100249129-A1 COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS ABBOTT LABORATORIES (US) 2010-09-30 US disclosed
WO-2010111572-A1 COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS ABBOTT LABORATORIES (US) 2010-09-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100249129-A1 COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS CNR1, CNR2, GPR18 CFTR 923/4885CES2 444/4885MRGPRX4 109/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.